Management ChangeJun 4, 2026, 08:31 AM
Prenetics Appoints Hudson Leogrande to Board; IM8 ARR to hit $300M
AI Summary
Prenetics Global Limited announced the appointment of Hudson Leogrande, Founder and CEO of Comfrt, to its Board of Directors as an independent director. This appointment enhances the company's corporate governance, with three of its four directors now independent, and brings significant expertise in scaling direct-to-consumer brands through social commerce. IM8, Prenetics' premium health brand, has achieved rapid growth, surpassing $100 million in annualized recurring revenue in 11 months and is projected to reach $250 million to $300 million ARR by the end of 2026, with full-year 2026 revenue guidance raised to $190 million to $210 million.
Key Highlights
- Hudson Leogrande, Founder and CEO of Comfrt, appointed as an independent director to Prenetics' Board.
- With this appointment, three of Prenetics' four directors are now independent.
- Comfrt, founded by Mr. Leogrande, is projected to exceed $1 billion in annual revenue in 2026.
- IM8, Prenetics' health brand, crossed $100 million in annualized recurring revenue in 11 months.
- IM8 is projected to reach $250 million to $300 million in annualized recurring revenue by end of 2026.
- Prenetics raised its full-year 2026 IM8 revenue guidance to $190 million to $210 million.
- David Vanderveen resigned from the Prenetics Board of Directors.
Price Impact
More from PRE